Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China Jun 11, 2019 Life Science
Shanghai’s Brii Bioscience Invests in Artizan; Gains China Rights to Microbiota Treatment for IBD Jun 11, 2019 Life Science
Everest Medicines Acquires China Rights to Kidney Disease Treatment in $121 Million Pact Jun 10, 2019 Life Science
CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC Jun 5, 2019 Life Science
Frontage Holdings Corporation Celebrates a Successful Initial Public Offering on the HKEx Jun 4, 2019 Life Science
Jiangsu Provincial Institute of Materia Medica Selects Provantis Preclinical SaaS Solution Jun 4, 2019 Life Science
